HTB

IAS 7 Kuala Lumpur 2013

7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur

High prices for antiretrovirals in middle-income countries outside Africa

Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses

PrEP gives little extra benefit in attempted conception if male partner is on ART

7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur

WHO 2013 guidelines: what about the missing formulations?

WHO 2013 guidelines: when the risk:benefit may not favour starting at CD4 count of 500

Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects

Dolutegravir update: treatment-naive and -experienced patients and drug resistance

Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013

Non-standard combinations: NRTI-sparing combinations

ARVs and bone health: the role of NRTIs in second-line therapy

No viral load rebound off-ART following stem cell transplant: two “cure” cases using reduced intensity conditioning chemotherapy and CCR5 d-32 negative donors

HIV cure research: further capsules at IAS 2013

Partner-dependent immune differences may protect against HIV infection

Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes